The effect of sublingual captopril versus intravenous enalaprilat on angiotensin II plasma levels.
A 44-year-old woman, with a history of familial adenomatous polyposis, complicated by carcinoma of the colon, for which a proctocolectomy had been performed, now presented with metastasis located in the pancreas. Treatment consisted of chemotherapy followed by a partial pancreaticoduodenectomy. Due to ischemia, resection of the small intestines was performed the same day. After admission, a transesophageal echocardiography showed an ejection fraction of 40%. Because enteral administration of drugs was impossible, intravenous enalaprilat 2 mg once a day for 1 day followed by sublingual captopril 25 mg twice a day were started. Blood samples were taken before and after administration. After 1 day of sublingual captopril treatment the angiotensin II level decreased with more than 50%, comparable to the decrease seen after intravenous administration of enalaprilat. Sublingual captopril has been used in the treatment of hypertensive crisis and heart failure. Although frequently reported, no study has investigated the effect on angiotensin II levels after sublingual administration in heart failure patients. This case-report demonstrated that sublingual administration of 25 mg captopril twice a day yielded a considerable decrease in angiotensin II plasma levels which was comparable to the effect seen after an intravenous administration of 2 mg enalaprilat.
van Onzenoort
Hein A
HA
Department of Clinical Pharmacy and Toxicology, University Hospital Maastricht, NL-6202 AZ Maastricht, The Netherlands. HVON@kfls.azm.nl
Bussink
Michiel
M
Menheere
Paul P
PP
van Mook
Walther N
WN
van der Kuy
Paul-Hugo M
PH
D000230:Adenocarcinoma / Q000473:pathology / Q000601:surgery; D000286:Administration, Sublingual; D000328:Adult; D000804:Angiotensin II / Q000097:blood*; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D002216:Captopril / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D015773:Enalaprilat / Q000008:administration & dosage / Q000009:adverse effects / Q000494:pharmacology*; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D044483:Intestinal Polyposis / Q000473:pathology / Q000601:surgery; D010190:Pancreatic Neoplasms / Q000556:secondary; D010288:Parenteral Nutrition
D000806:Angiotensin-Converting Enzyme Inhibitors; D000804:Angiotensin II; D002216:Captopril; D015773:Enalaprilat